Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 14:2018:8047610.
doi: 10.1155/2018/8047610. eCollection 2018.

Role of Muramyl Dipeptide in Lipopolysaccharide-Mediated Biological Activity and Osteoclast Activity

Affiliations
Review

Role of Muramyl Dipeptide in Lipopolysaccharide-Mediated Biological Activity and Osteoclast Activity

Hideki Kitaura et al. Anal Cell Pathol (Amst). .

Abstract

Lipopolysaccharide (LPS) is an endotoxin and bacterial cell wall component that is capable of inducing inflammation and immunological activity. Muramyl dipeptide (MDP), the minimal essential structural unit responsible for the immunological activity of peptidoglycans, is another inflammation-inducing molecule that is ubiquitously expressed by bacteria. Several studies have shown that inflammation-related biological activities were synergistically induced by interactions between LPS and MDP. MDP synergistically enhances production of proinflammatory cytokines that are induced by LPS exposure. Injection of MDP induces lethal shock in mice challenged with LPS. LPS also induces osteoclast formation and pathological bone resorption; MDP enhances LPS induction of both processes. Furthermore, MDP enhances the LPS-induced receptor activator of NF-κB ligand (RANKL) expression and toll-like receptor 4 (TLR4) expression both in vivo and in vitro. Additionally, MDP enhances LPS-induced mitogen-activated protein kinase (MAPK) signaling in stromal cells. Taken together, these findings suggest that MDP plays an important role in LPS-induced biological activities. This review discusses the role of MDP in LPS-mediated biological activities, primarily in relation to osteoclastogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic structure of peptidoglycan and MDP. PGN, a major component of the bacterial cell membrane, is a crystal lattice structure formed by the combination of linear chains of two alternating amino sugars, GlcNAc and MurNAc. MDP consists of MurNAc and two amino acids, l-Ala and d-Glu. M: MurNAc; G: GluNAc.
Figure 2
Figure 2
Schematic of the role of MDP in LPS-induced osteoclast formation. LPS induces TNF-α expression; MDP further enhances this TNF-α expression. MDP-enhanced, LPS-induced TNF-α may lead to an increase in RANKL expression by stromal cells. Furthermore, LPS also acts to induce RANKL expression; MDP further enhances this RANKL expression in stromal cells. The MDP-enhanced, LPS-induced TNF-α production synergistically interacts with MDP-enhanced, LPS-induced RANKL, thereby leading to increased induction of osteoclastogenesis. Therefore, the role of MDP in LPS-induced osteoclast formation in vivo may be to strongly promote the induction of this process.

References

    1. Abu-Amer Y., Ross F. P., Edwards J., Teitelbaum S. L. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. The Journal of Clinical Investigation. 1997;100(6):1557–1565. doi: 10.1172/JCI119679. - DOI - PMC - PubMed
    1. Chiang C. Y., Kyritsis G., Graves D. T., Amar S. Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. Infection and Immunity. 1999;67(8):4231–4236. - PMC - PubMed
    1. Khedoe P., de Kleijn S., van Oeveren-Rietdijk A. M., et al. Acute and chronic effects of treatment with mesenchymal stromal cells on LPS-induced pulmonary inflammation, emphysema and atherosclerosis development. PLoS One. 2017;12(9, article e0183741) doi: 10.1371/journal.pone.0183741. - DOI - PMC - PubMed
    1. Rosadini C. V., Kagan J. C. Early innate immune responses to bacterial LPS. Current Opinion in Immunology. 2017;44:14–19. doi: 10.1016/j.coi.2016.10.005. - DOI - PMC - PubMed
    1. Lopes P. C. LPS and neuroinflammation: a matter of timing. Inflammopharmacology. 2016;24(5):291–293. doi: 10.1007/s10787-016-0283-2. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources